论文信息 - Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: First results from STAMPEDE (MRC PR08, CRUK/06/019), a randomized controlled trial. - 字舞流文

Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: First results from STAMPEDE (MRC PR08, CRUK/06/019), a randomized controlled trial.

M. Parmar | M. Sydes | D. Dearnaley | N. James | N. Clarke | M. Mason | G. Bertelli | N. Srihari | J. O’Sullivan | G. Thalmann | G. Jovic | J. Russell | John Anderson | J. Dwyer | A. Birtle | A. Protheroe | D. Sheehan | A. Ritchie | Karen Sanders